Combined detection of serum IL-6 and CEA contributes to the diagnosis of lung adenocarcinoma in situ
PeerJ · 2024
DOI: 10.7717/peerj.17141 ↗Kurz gefasst
Fachartikel in der Zeitschrift PeerJ, 2024. Verfasst von Jing Pan und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Laboratory, Rehabilitation Hospital Affiliated to Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian, China. Hauptthemen laut MEDLINE: Adenocarcinoma in Situ, Adenocarcinoma of Lung, Antigens, Neoplasm, Lung Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Vertical Project of Fujian Province, Joint fund of Science and Technology Innovation of Fujian province, Key Project of Natural Science Foundation of Fujian province.
Abstract (Originalsprache)
Background
Effective discrimination of lung adenocarcinoma (LUAD) in situ (AIS) from benign pulmonary nodules (BPN) is critical for the early diagnosis of AIS. Our pilot study in a small cohort of 90 serum samples has shown that serum interleukin 6 (IL-6) detection can distinguish AIS from BPN and health controls (HC). In this study, we intend to comprehensively define the diagnostic value of individual and combined detection of serum IL-6 related to the traditional tumor markers carcinoembryonic antigen (CEA) and cytokeratin 19 fragment (CYFRA21-1) for AIS.
Methods
The diagnostic performance of serum IL-6 along with CEA and CYFRA21-1 were evaluated in a large cohort of 300 serum samples by a chemiluminescence immunoassay and an electrochemiluminescence immunoassay. A training set comprised of 65 AIS, 65 BPN, and 65 HC samples was used to develop the predictive model for AIS. Data obtained from an independent validation set was applied to evaluate and validate the predictive model.
Results
In the training set, the levels of serum IL-6 and CEA in the AIS group were significantly higher than those in the BPN/HC group ( P < 0.05). There was no significant difference in serum CYFRA21-1 levels between the AIS group and the BPN/HC group ( P > 0.05). Serum IL-6 and CEA levels for AIS patients showed an area under the curve (AUC) of 0.622 with 23.1% sensitivity at 90.7% specificity, and an AUC of 0.672 with 24.6% sensitivity at 97.6% specificity, respectively. The combination of serum IL-6 and CEA presented an AUC of 0.739, with 60.0% sensitivity at 95.4% specificity. The combination of serum IL-6 and CEA showed an AUC of 0.767 for AIS patients, with 57.1% sensitivity at 91.4% specificity in the validation set.
Conclusions
IL-6 shows potential as a prospective serum biomarker for the diagnosis of AIS, and the combination of serum IL-6 with CEA may contribute to increased accuracy in AIS diagnosis. However, it is worth noting that further research is still necessary to validate and optimize the diagnostic efficacy of these biomarkers and to address potential sensitivity limitations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Laboratory, Rehabilitation Hospital Affiliated to Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian, China.
- Shengli Clinical Medical College, Fujian Medical University, Fuzhou, China.
- Department of Clinical Laboratory, Fujian Provincial Hospital, Fuzhou, China.
- Integrated Chinese and Western Medicine College, Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian, China.
- Center for Experimental Research in Clinical Medicine, Fujian Provincial Hospital, Fuzhou, Fujian, China.
- Fujian Provincial Key Laboratory of Critical Care Medicine, Fujian Provincial Key Laboratory of Cardiovascular Disease, Fuzhou, China.
Förderung
- Medical Vertical Project of Fujian Province
- Joint fund of Science and Technology Innovation of Fujian province
- Key Project of Natural Science Foundation of Fujian province
- Science and Technology Innovation of Fujian province
Zitieren
APA
Pan, J., Zhuang, W., Xia, Y., Huang, Z., Zheng, Y., Wang, X., & Huang, Y. (2024). Combined detection of serum IL-6 and CEA contributes to the diagnosis of lung adenocarcinoma in situ. PeerJ. https://doi.org/10.7717/peerj.17141
Vancouver
Pan J, Zhuang W, Xia Y, Huang Z, Zheng Y, Wang X, et al. Combined detection of serum IL-6 and CEA contributes to the diagnosis of lung adenocarcinoma in situ. PeerJ. 2024. doi:10.7717/peerj.17141
BibTeX
@article{Pan2024,
author = {Pan, Jing and Zhuang, Wanzhen and Xia, Yu and Huang, Zhixin and Zheng, Yue and Wang, Xin and Huang, Yi},
title = {Combined detection of serum IL-6 and CEA contributes to the diagnosis of lung adenocarcinoma in situ},
journal = {PeerJ},
year = {2024},
doi = {10.7717/peerj.17141}
}
EUVIMED